I am obviously not wishing for the illness to expand but given that it will and that chest x-rays are a tool for treatment and diagnosis then I would have thought PME would see further use above that expected.
This makes me think that the long term will me this an upside risk that the market is not yet considering.
It is true that medical service companies make money from illness but that is how you get good products available for treatment. PME has potential to provide better treatment tools than others with a great product.
All IMHO
Ann: PME - Showcase AI Accelerator at RSNA, page-28
Add PME (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$168.02 |
Change
5.850(3.61%) |
Mkt cap ! $17.55B | |||
| Open | High | Low | Value | Volume |
| $164.18 | $169.07 | $164.18 | $39.42M | 235.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 780 | $168.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $169.65 | 780 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PME (ASX) Chart |